文献速递神经核医学肿瘤 PET/CT放射性药物与辐射防护

肌萎缩侧索硬化症全身脑-体代谢耦合模式:跨临床表型的全身[18F]FDG PET/CT研究

Systemic brain-body metabolic coupling patterns in amyotrophic lateral sclerosis: a whole-body [18F] fluorodeoxyglucose PET/CT study across clinical phenotypes.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-27

本研究纳入121例ALS患者和83例对照,行全身[18F]FDG PET/CT,提取脑区及11个外周器官的SUVr、SUVmean和SUVmax,构建代谢相关网络。结果显示ALS患者存在脑区及外周器官代谢改变,不同临床表型具有特征性脑-体耦合模式,部分外周代谢指标与生存相关。

要点

  • ALS患者额叶和运动皮质低代谢,后扣带回和海马旁回高代谢。
  • 晚期King分期与脑-心代谢耦合增强相关,快速进展型脑-脊髓耦合增强。
  • 校正后仅固有脊柱肌SUVr与不良预后显著相关。

核心结论

  • ALS是以脑-体代谢网络广泛重塑为特征的系统性疾病。
  • 全身[18F]FDG PET/CT可检测多器官代谢异常并揭示系统间耦合机制。
  • 该技术为ALS分层、预后预测和个体化管理提供影像生物标志物。

研究设计与样本

  • 研究纳入121例ALS患者和83例对照,均行全身[18F]FDG PET/CT。
  • 从脑区和11个外周器官提取SUVr、SUVmean和SUVmax。
  • 构建区域间代谢相关网络,并按King分期、进展速率、起病部位、基因突变和非运动症状进行亚组分析。
  • 通过纵向随访分析代谢改变与生存的关联。

主要发现

  • 与对照相比,ALS患者额叶和运动皮质低代谢,后扣带回和海马旁回高代谢。
  • 外周改变包括肝、脾、胸段脊髓和脊柱肌代谢增高,肺代谢减低。
  • 晚期King分期与脑-心代谢耦合增强相关。
  • 快速进展亚型表现为脑-脊髓耦合增强,伴小肠和胸段脊髓低代谢。
  • 延髓起病ALS表现为心脏代谢增高但脑-心耦合减低。

关键数值与推荐

  • 未校正分析中,肺和肠道低代谢及固有脊柱肌和颈段脊髓高代谢与不良预后显著相关。
  • Benjamini–Hochberg FDR校正后,仅固有脊柱肌SUVr与不良预后显著相关。

临床怎么用

  • 全身[18F]FDG PET/CT可用于评估ALS患者多器官代谢异常。
  • 脑-体代谢耦合模式有助于识别不同临床表型和预后风险。
  • 固有脊柱肌SUVr可能作为预后标志物,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder involving both central and peripheral systems. Its marked heterogeneity and variable prognosis suggest pathophysiology beyond motor neuron degeneration. This study aimed to map brain–body metabolic networks using whole-body [18F]FDG PET/CT, characterize systemic remodeling, and to identify clinically meaningful brain-organ coupling axes and peripheral prognostic markers (lung, small intestine, cervical cord, intrinsic spinal muscles), providing imaging candidates for phenotype-informed stratification and hypothesis generation for future multimodal studies. METHODS: We enrolled 121 ALS patients and 83 controls who underwent whole-body [18F]FDG PET/CT. Standardized uptake value ratios (SUVr), mean Standardized uptake value (SUVmean), and maximum Standardized uptake value (SUVmax) were extracted from brain regions and 11 peripheral organs. Interregional metabolic correlation networks were constructed, and subgroup analyses were performed according to King's stage, progression rate, site of onset, genetic mutations, and non-motor symptoms (NMS). Associations between metabolic alterations and survival were examined using longitudinal follow-up. RESULTS: Compared to controls, ALS patients exhibited hypometabolism in the frontal lobe and motor cortex, but hypermetabolism in the posterior cingulate and parahippocampal regions. Peripheral alterations included increased metabolism in the liver, spleen, thoracic spinal cord, and spinal muscles, as well as reduced metabolism in the lungs. Brain–body network analysis revealed that advanced King's stages were associated with strengthened brain–heart metabolic coupling. Rapid progression subtypes exhibited enhanced brain-spinal cord coupling and concomitant hypometabolism in the small intestine and thoracic spinal cord. Bulbar-onset ALS demonstrated increased cardiac metabolism but reduced brain–heart coupling. Patients with genetic mutations or NMS exhibited disrupted brain–body co-variation. In unadjusted analyses, survival analysis demonstrated that lung and intestinal hypometabolism and hypermetabolism in the intrinsic spinal muscles and cervical spinal cord were significantly associated with poor prognosis; after Benjamini–Hochberg false discovery rate correction, only intrinsic spinal muscle SUVr remained significant. CONCLUSION: ALS is a systemic disorder characterized by widespread remodeling of brain–body metabolic networks. Whole-body [18F]FDG PET/CT enables the detection of multi-organ metabolic abnormalities and uncovers inter-system coupling mechanisms, offering biomarkers for stratification, prognosis prediction, and individualized management.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hou M, Xie X, Hu J, et al. Systemic brain-body metabolic coupling patterns in amyotrophic lateral sclerosis: a whole-body [18F] fluorodeoxyglucose PET/CT study across clinical phenotypes. Eur J Nucl Med Mol Imaging. 2026. PMID: 41588209. doi:10.1007/s00259-026-07765-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。